[go: up one dir, main page]

MX2018014743A - Metodo para tratar fibrosis hepatica. - Google Patents

Metodo para tratar fibrosis hepatica.

Info

Publication number
MX2018014743A
MX2018014743A MX2018014743A MX2018014743A MX2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A MX 2018014743 A MX2018014743 A MX 2018014743A
Authority
MX
Mexico
Prior art keywords
liver fibrosis
treating liver
treating
fibrosis
t2dm
Prior art date
Application number
MX2018014743A
Other languages
English (en)
Other versions
MX387070B (es
Inventor
Miao Zhenhua
Charo Israel
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2018014743A publication Critical patent/MX2018014743A/es
Publication of MX387070B publication Critical patent/MX387070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporciona un método para tratar fibrosis hepática con antagonistas de CCR2. La fibrosis hepática puede estar asociada con esteatohepatitis no alcohólica (NASH), enfermedad de hígado graso no alcohólico (NAFLD), cirrosis emergente, fibrosis hepática no cirrótica, diabetes mellitus tipo 2 (T2DM) o síndrome metabólico (MS).
MX2018014743A 2016-06-03 2017-06-02 Metodo para tratar fibrosis hepatica MX387070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345086P 2016-06-03 2016-06-03
PCT/US2017/035628 WO2017210526A1 (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Publications (2)

Publication Number Publication Date
MX2018014743A true MX2018014743A (es) 2019-04-11
MX387070B MX387070B (es) 2025-03-04

Family

ID=60479090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014743A MX387070B (es) 2016-06-03 2017-06-02 Metodo para tratar fibrosis hepatica

Country Status (15)

Country Link
US (3) US10682344B2 (es)
EP (1) EP3463350B1 (es)
JP (2) JP2019517523A (es)
KR (1) KR102444366B1 (es)
CN (2) CN115154467B (es)
AU (1) AU2017274521B2 (es)
BR (1) BR112018074452A2 (es)
CA (1) CA3025671C (es)
ES (1) ES2966111T3 (es)
IL (1) IL263245B (es)
MX (1) MX387070B (es)
RU (1) RU2740902C2 (es)
SG (2) SG10202012080UA (es)
WO (1) WO2017210526A1 (es)
ZA (1) ZA201807992B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
ES2966111T3 (es) * 2016-06-03 2024-04-18 Chemocentryx Inc Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
IL311409A (en) * 2016-11-10 2024-05-01 Galmed Res And Development Ltd Aramchol for use in fibrosis treatment
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
JP7181386B2 (ja) * 2018-06-12 2022-11-30 スーチョワン ハイスコ ファーマスーティカル カンパニー リミテッド 甲状腺ホルモン受容体アゴニスト及びその用途
US20210322324A1 (en) * 2018-08-14 2021-10-21 Avolynt Method for treating primary sclerosing cholangitis
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
EP3890747A4 (en) * 2018-12-05 2022-08-03 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
PH12021552782A1 (en) 2019-05-08 2023-01-16 Aligos Therapeutics Inc Modulators of thr-㟠and methods of use thereof
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
BR112022001637A2 (pt) 2019-07-30 2022-03-22 Kobiolabs Inc Kit para predizer ou diagnosticar doença hepática gordurosa não alcoólica e método para diagnosticar doença hepática gordurosa não alcoólica
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN116942684A (zh) * 2020-02-20 2023-10-27 甘莱制药有限公司 一种用于治疗脂肪性肝炎的药物组合物及其制备方法
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2021358793B2 (en) 2020-10-08 2024-06-27 Curome Biosciences Co., Ltd. Pharmaceutical composition for preventing or treating cholestatic liver disease, containing betaeta-lapachone as active ingredient
CN120899882A (zh) * 2025-06-16 2025-11-07 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) Klb蛋白在制备治疗血吸虫感染的药物上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005250156A1 (en) * 2004-05-26 2005-12-15 Janssen Pharmaceutica N.V. Mercaptoimidazoles as CCR2 receptor antagonists
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
MX2007008474A (es) 2005-01-14 2008-02-19 Chemocentryx Inc Sulfonamidas de heteroarilo y ccr2.
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007106797A2 (en) * 2006-03-14 2007-09-20 Janssen Pharmaceutica, Nv A method of use for substituted dipiperidine ccr2 antagonists
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
CN101511800B (zh) * 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
CN101820881B (zh) 2007-07-12 2013-05-01 坎莫森特里克斯公司 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
RU2547595C2 (ru) * 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
PE20121614A1 (es) * 2009-12-17 2012-12-21 Boehringer Ingelheim Int Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
CN103391931A (zh) * 2011-02-25 2013-11-13 辉瑞有限公司 治疗肝纤维化的方法
AU2012308491B2 (en) * 2011-09-16 2016-01-07 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
BR112014027884A2 (pt) * 2012-05-09 2017-06-27 Boehringer Ingelheim Int combinações farmacêuticas para tratamento de distúrbios metabólicos
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
ES2966111T3 (es) * 2016-06-03 2024-04-18 Chemocentryx Inc Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática

Also Published As

Publication number Publication date
CA3025671C (en) 2024-10-01
WO2017210526A1 (en) 2017-12-07
KR102444366B1 (ko) 2022-09-19
KR20190026687A (ko) 2019-03-13
RU2740902C2 (ru) 2021-01-21
CN115154467B (zh) 2024-08-23
CN109475537A (zh) 2019-03-15
ES2966111T3 (es) 2024-04-18
RU2018145459A3 (es) 2020-07-09
SG10202012080UA (en) 2021-01-28
NZ748675A (en) 2024-12-20
US20220313668A1 (en) 2022-10-06
IL263245A (en) 2018-12-31
US11357760B2 (en) 2022-06-14
SG11201810602YA (en) 2018-12-28
JP2019517523A (ja) 2019-06-24
US20170348293A1 (en) 2017-12-07
US20200268727A1 (en) 2020-08-27
ZA201807992B (en) 2023-10-25
CN115154467A (zh) 2022-10-11
EP3463350A4 (en) 2020-01-29
AU2017274521A1 (en) 2018-12-13
JP2023022227A (ja) 2023-02-14
MX387070B (es) 2025-03-04
JP7431931B2 (ja) 2024-02-15
EP3463350B1 (en) 2023-09-13
RU2018145459A (ru) 2020-07-09
BR112018074452A2 (pt) 2019-03-19
CA3025671A1 (en) 2017-12-07
IL263245B (en) 2021-09-30
AU2017274521B2 (en) 2021-08-19
US10682344B2 (en) 2020-06-16
EP3463350A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2018014743A (es) Metodo para tratar fibrosis hepatica.
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
MX2024010201A (es) Analogos de incretina y sus usos.
MX2025003745A (es) Analogos de incretina y sus usos
AR118965A1 (es) Combinaciones para el tratamiento de nash / nafld y enfermedades relacionadas
MX2017011586A (es) Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
MX2018009170A (es) Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y esteatohepatitis no alcoholica (nash) y usos de estos.
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
AR104844A1 (es) Método para recubrimiento de un chupetín
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
EA202191379A1 (ru) Комбинированное лечение nafld и nash
BR112018071618A2 (pt) métodos, composições e usos relacionados aos mesmos
EP3910040A4 (en) COMPOSITION CONTAINING A CIS-?,?-DIFLUOROETHYLENE
BR112018071601A2 (pt) métodos, composições e usos relacionados aos mesmos
MX2022000388A (es) Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4.
CY1124611T1 (el) Θεραπειες μη-αλκοολικης στεατοηπατιτιδας (nash)
PL128003U1 (pl) Pływalnia lub basen z ruchomym dnem
EA201890007A1 (ru) Мультипептидная композиция
Verdin El Retablo de Nuestra Senora de los Olmos en Torre de Juan Abad: 8 Imagines, 8 Composiciones
UA105533U (uk) Спосіб визначення ефективності корекції при експериментальному цукровому діабеті 1-го типу
BR112015021992A8 (pt) métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld), se um indivíduo com esteatose não alcoólica tem esteatohepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash